Welcome to our dedicated page for Inotiv news (Ticker: NOTV), a resource for investors and traders seeking the latest updates and insights on Inotiv stock.
Inotiv, Inc. (NASDAQ: NOTV) is a contract research organization focused on nonclinical and analytical drug discovery and development services and research models and related products and services. The NOTV news feed on Stock Titan brings together company-issued updates, earnings announcements, strategic collaborations, legal and regulatory disclosures, and operational developments that shape the outlook for this preclinical services provider.
Investors and industry observers following Inotiv’s news can track segment trends in its Discovery and Safety Assessment (DSA) and Research Models and Services (RMS) businesses, including commentary on safety assessment, general toxicology, biotherapeutic analysis, discovery and translational sciences, and non-human primate (NHP) product and service revenues. Regular earnings releases and preliminary results updates provide insight into revenue mix, operating performance, backlog, and book-to-bill ratios across these segments.
Inotiv’s news flow also covers strategic initiatives such as its collaboration with VUGENE to integrate an AI-enabled bioinformatics and computational platform into its Discovery & Translational Sciences Division, and its initiative to leverage LifeNet Health’s TruVivo system to incorporate human-relevant in vitro models into its disease pharmacology offering. These items offer context on how the company is incorporating new approach methodologies and data-driven tools into early-stage research support.
Regulatory and legal developments are another key component of NOTV news. Filings and press releases have addressed matters such as settlements of securities class action and derivative litigation, updates on investigations related to non-human primate importations, and disclosures about a cybersecurity incident and related privacy class actions. Capital structure updates, including engagement of financial advisors to explore debt refinancing alternatives and activity on credit facilities, also appear in the company’s communications.
By reviewing the NOTV news page, readers can follow how Inotiv communicates its financial results, operational progress, collaborations, risk factors, and governance changes over time, all directly based on its public disclosures.
Inotiv (NASDAQ:NOTV), a leading contract research organization focused on nonclinical drug discovery services and research models, announced its participation in three upcoming investor conferences in September 2025.
CEO Robert Leasure Jr. and CFO Beth Taylor will attend the H.C. Wainwright Global Investment Conference (September 10), the Baird Global Healthcare Conference (September 9), and the Lake Street Capital Markets Best Ideas Growth Conference (September 11). All events will take place in New York, NY, featuring presentations and one-on-one meetings with institutional investors.
Inotiv (NASDAQ:NOTV) reported strong Q3 FY2025 financial results with revenue increasing 23.5% to $130.7 million. The growth was driven by a 34.1% increase in Research Models & Services (RMS) revenue to $82.5 million and an 8.9% increase in Discovery & Safety Assessment (DSA) revenue to $48.2 million.
The company reduced its net loss to $17.6 million (13.5% of revenue) compared to $26.1 million in Q3 FY2024. Adjusted EBITDA improved significantly to $11.6 million (8.9% of revenue) from $0.1 million year-over-year. DSA backlog stood at $134.3 million with a book-to-bill ratio of 1.07x.
Notable developments include the SEC concluding its investigation related to non-human primate importations without recommending enforcement action, and a $10 million accrual for ongoing securities lawsuits, expected to be fully recovered through insurance.
Inotiv (NASDAQ:NOTV), a leading contract research organization, reported strong financial results for Q3 FY2025. Revenue increased 23.5% to $130.7 million, driven by significant growth in both Research Models & Services (RMS) and Discovery & Safety Assessment (DSA) segments.
The company reduced its net loss to $17.6 million (13.5% of revenue) from $26.1 million in Q3 FY2024. Adjusted EBITDA improved substantially to $11.6 million (8.9% of revenue) compared to $0.1 million last year. DSA segment showed strong momentum with a book-to-bill ratio of 1.07x and net awards increasing 25% year-over-year.
Notable developments include the SEC concluding its investigation related to non-human primate importations without recommending enforcement action, and a $10 million accrual for ongoing securities lawsuits, expected to be fully recovered through insurance.
Inotiv (NASDAQ:NOTV), a leading contract research organization focused on nonclinical and analytical drug discovery services, has scheduled its fiscal 2025 third quarter financial results announcement for August 6, 2025, after market close.
The company will host a conference call at 4:30 PM Eastern Time on the same day to discuss the results. Investors can access the call through domestic (1-800-245-3047) or international (1-203-518-9765) dial-in numbers using Conference ID: INOTIV. A live webcast will be available on the company's investor relations website, with a replay accessible afterward.
Inotiv (NASDAQ: NOTV), a contract research organization focused on nonclinical and analytical drug discovery and development services, has announced its participation in the upcoming Jefferies Global Healthcare Conference in New York. Robert Leasure Jr., President and CEO, will deliver a presentation on June 4 at 3:45 p.m. ET. The presentation will be available via live webcast through the company's investor relations website section and will remain accessible for approximately 90 days after the event.
Inotiv (NASDAQ: NOTV), a contract research organization focused on nonclinical and analytical drug discovery and development services, has scheduled its fiscal 2025 second quarter financial results announcement for Wednesday, May 7, 2025, after market close.
The company will host a conference call at 4:30 p.m. Eastern Time on the same day to discuss the results. Participants can join via phone using the following numbers:
- Domestic: 1-800-245-3047
- International: 1-203-518-9765
- Conference ID: INOTIV
A live webcast will be available through the Investors section of Inotiv's website, with a replay accessible afterward at ir.inotiv.com/overview/default.aspx.
Inotiv (NOTV) reported Q1 FY2025 financial results showing an 11.5% revenue decline to $119.9 million compared to Q1 FY2024. The company experienced decreased revenue across both segments: Research Models & Services (RMS) declined 15.1% to $77.1 million, while Discovery & Safety Assessment (DSA) fell 4.2% to $42.8 million.
The company reported a net loss of $27.6 million (23.0% of revenue) compared to $15.8 million loss in Q1 FY2024. Adjusted EBITDA decreased to $2.6 million (2.2% of revenue) from $9.6 million in the prior year. The company strengthened its liquidity position by raising $27.5 million through a public offering of 6.9 million common shares at $4.25 per share.
DSA backlog stood at $130.4 million with a book-to-bill ratio of 1.01x. The company expects annual cost savings of $4.0-$5.0 million following the completion of its North American RMS site optimization plan.
Inotiv (NASDAQ: NOTV), a contract research organization focused on nonclinical and analytical drug discovery services, has scheduled its fiscal 2025 first quarter financial results announcement for Wednesday, February 5, 2025, after market close. The results will cover the period ended December 31, 2024.
The company will host a conference call at 4:30 p.m. Eastern Time on the same day to discuss the results. Participants can join via phone using the following numbers: 1-800-579-2543 (Domestic) or 1-785-424-1789 (International), with Conference ID: INOTIV. A live webcast will be available through the company's Investors section website, with a replay accessible afterward.
Inotiv (NOTV) has completed an equity offering, raising approximately $3.6 million in net proceeds through the issuance of 900,000 additional common shares at $4.25 per share. The offering, which closed on December 30, 2024, was executed in connection with a previously announced underwritten public offering. Lake Street Capital Markets acted as the sole book-running manager. The company plans to utilize the proceeds for working capital, capital expenditures, and general corporate purposes. The offering was conducted under a shelf registration statement that became effective on August 31, 2022.